205 related articles for article (PubMed ID: 36471407)
41. A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
Xu X; Wang H; Yu Z; Chen X
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1825-1827. PubMed ID: 35364706
[TBL] [Abstract][Full Text] [Related]
42. Pralsetinib for the treatment of a
Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
44. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
45. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
[TBL] [Abstract][Full Text] [Related]
46. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
47. Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study.
Seki Y; Yoshida T; Kohno T; Masuda K; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Kuwano K; Ohe Y
Respir Investig; 2022 Nov; 60(6):852-856. PubMed ID: 36089506
[TBL] [Abstract][Full Text] [Related]
48. [Lung cancer treated abroad with receptor tyrosine kinase inhibitor].
Eide IJZ; Brustugun OT
Tidsskr Nor Laegeforen; 2021 Sep; 141():. PubMed ID: 34505490
[TBL] [Abstract][Full Text] [Related]
49. Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer.
Gow CH; Liu YN; Li HY; Hsieh MS; Chang SH; Luo SC; Tsai TH; Chen PL; Tsai MF; Shih JY
Neoplasia; 2018 Aug; 20(8):838-847. PubMed ID: 30015159
[TBL] [Abstract][Full Text] [Related]
50. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
51. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
52. Use of on-therapy ctDNA monitoring in a patient with
Yeung V; Kim C; Kiedrowski LA; Liu SV; Reuss JE
Transl Lung Cancer Res; 2022 Jan; 11(1):111-116. PubMed ID: 35242632
[TBL] [Abstract][Full Text] [Related]
53. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
54. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
[TBL] [Abstract][Full Text] [Related]
55. A novel PIBF1-RET gene fusion identified from a stage IA lung adenocarcinoma: A case report.
Zhao W; Sun J; Zhu H; Zhao G
Medicine (Baltimore); 2023 Jul; 102(29):e34305. PubMed ID: 37478265
[TBL] [Abstract][Full Text] [Related]
56. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
57. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
58. Identification and Validation of Noncanonical RET Fusions in Non-Small-Cell Lung Cancer through DNA and RNA Sequencing.
Xiang C; Guo L; Zhao R; Teng H; Wang Y; Xiong L; Han Y
J Mol Diagn; 2022 Apr; 24(4):374-385. PubMed ID: 35063667
[TBL] [Abstract][Full Text] [Related]
59. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
60. Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with
An L; Chen P; Wang J; Qin X; Liu T; Gao Y; Wang P; Zhang D; Fang X; Zhang Z
Front Oncol; 2022; 12():1024365. PubMed ID: 36568233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
